SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Diplomat Pharmacy, Inc. To Contact The Firm Before Lead Plaintiff Deadline

Flagge der World Health Organisation (WHO) ©United States Mission Geneva https://www.flickr.com/people/41916075@N06

PR Newswire

NEW YORK, Jan. 6, 2017

NEW YORK, Jan. 6, 2017 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Diplomat Pharmacy, Inc. ("Diplomat" or the "Company") (NYSE:DPLO) of the January 9, 2017 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company and certain officers.

The lawsuit has been filed in the U.S. District Court for the Eastern District of Michigan on behalf of all those who purchased Diplomat stock or options between October 9, 2014 and November 2, 2016 (the "Class Period"). The case, Zimmerman v. Diplomat Pharmacy, Inc. et al, No. 16-cv-14005 was filed on November 10, 2016, and has been assigned to Judge Stephanie Dawkins Davis.

The lawsuit focuses on whether the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) the Company lacked adequate internal controls over its financial reporting; (2) as a result the Company could not adequately calculate direct and indirect remuneration ("DIR") fees; (3) the Company's hepatitis C segment was not performing as previously disclosed to investors; (4) and therefore, the Company had overstated its full-year 2016 guidance.

Specifically, on November 2, 2016, Diplomat announced third quarter 2016 results that were below investors' expectations and lowered its full year 2016 guidance. The Company's Chief Executive Officer attributed the poor operating results to "softness in the hepatitis C business" and DIR fees.

On this news, Diplomat's share price fell from $22.38 per share on November 2, 2016 to a closing price of $12.95 on November 3, 2016—a $9.43 or a 42.1% drop.

Request more information now by clicking here: www.faruqilaw.com/DPLO. There is no cost or obligation to you.

Take Action

ARIVA.DE Börsen-Geflüster

Kurse

Dilomat Pharmacy

0,00%

If you invested in Diplomat stock or options between October 9, 2014 and November 2, 2016 and would like to discuss your legal rights, visit www.faruqilaw.com/DPLO. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com. Faruqi & Faruqi, LLP also encourages anyone with information regarding Diplomat's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class that is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

FARUQI & FARUQI, LLP
685 Third Avenue, 26^th Floor
New York, NY 10017
Attn: Richard Gonnello, Esq.
rgonnello@faruqilaw.com
Telephone: (877) 247-4292 or (212) 983-9330

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-faruqi--faruqi-llp-encourages-investors-who-suffered-losses-in-excess-of-100000-investing-in-diplomat-pharmacy-inc--to-contact-the-firm-before-lead-plaintiff-deadline-300386694.html

SOURCE Faruqi & Faruqi, LLP

Mehr Nachrichten zur Dilomat Pharmacy Aktie kostenlos abonnieren

E-Mail-Adresse

Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.